Please login to the form below

Not currently logged in

Iris Pauporté joins OSE Immunotherapeutics

She becomes clinical project director at the French biotech

OSE Immunotherapeutics Iris PauportéNantes, France-based biotech OSE Immunotherapeutics has bolstered its clinical team with the appointment of Iris Pauporté as clinical project director.

Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential in other cancer indications.

She brings over 20 years of biomedical and clinical research experience to the team, and joins from the French National Cancer Institute (INCa) where she supervised the insitute's breast cancer research programme.

Prior to this, Pauporté worked for the UNICANCER hospital group as a project leader overseeing both clinical research and regulatory affairs. She also brings experience as a research coordinator at Takeda Laboratories, where she served between 1997 and 2004.

Alain Chatelin, medical director at OSE Immunotherapeutics, said: “We are very pleased to have Iris join our team.

“She brings significant expertise in clinical research and a network of opinion leaders in oncology and immuno-oncology.”

28th September 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...